Skip to main content

Sofinnova Partners — Portfolio, Page 6

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

148
Companies
$6.3B
Total invested
$48.1M
Avg. check
26
Industries
Biotechnology 20Health Care 8Pharmaceutical 8Medical 5Medical Device 4Therapeutics 4+20 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 121144 of 148
Sitryx Therapeutics
September 2023

Sitryx is a biopharmaceutical company develops disease modifying therapeutics in immuno-oncology and immuno-inflammation.

Biotechnology · Oxford$39.0M Series A
Gradient Denervation Technologies
September 2023

Gradient Denervation Technologies develops a medical device for a transvascular treatment of pulmonary hypertension.

Biotechnology · Paris$15.0M Series A
Corwave
June 2023

CorWave is a medical device company developing innovative heart pumps.

Health Care · Paris$28.4M Series C
Mozart Therapeutics
June 2023

Mozart is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases.

Biotechnology · Seattle$25.0M Series A
TISSIUM
May 2023

TISSIUM develops biodegradable sealants and adhesives for wound closure in the field of minimally-invasive surgery.

Biotechnology · Paris$53.8M Series D
Werewool
May 2023

Werewool develops a fiber development platform to create biodegradable fibers.

Industrial · New York$3.7M Seed
Alia Therapeutics
April 2023

Alia Therapeutics is developing next-generation gene-editing medicines to cure rare genetic diseases.

Biotechnology · Trento$4.8M Seed
Kiro
March 2023

Kiro is an IT company that offers artificial intelligence, ergonomic design, and software development solutions for medical biology.

Artificial Intelligence (AI) · Paris$15.0M Series A
BioCorteX
March 2023

Capturing the human-bacterial relationship to address the seemingly impossible question - will this drug work [for me?]

Biotechnology · London$5.0M Seed
Nuage Therapeutics
March 2023

Nuage Therapeutics engages in developing drugs which target proteins in disordered regions for challenging indications faced by patients.

Biopharma · Barcelona$12.9M Seed
Amolyt Pharma
January 2023

Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders.

Biotechnology · Écully$138.6M Series C
Mablink Bioscience
October 2022

Mablink Bioscience is a biotechnology company.

Biotechnology · Lyon$30.1M Series A
Inspirna
July 2022

Inspirna is a biotechnology company developing drugs for the treatment of cancer.

Biotechnology · New York$55.1M Series D
DMC Biotechnologies
December 2021

DMC Biotechnologies produces bio-based chemicals using fermentation.

Biotechnology · Boulder$39.0M Series B
Synthace
November 2021

Synthace is a SaaS Life Sciences R&D Digital Experiment Platform.

Biotechnology · London$35.0M Series C
Home Biosciences
November 2021

Home Biosciences is a European venture builder dedicated to biotech.

Biotechnology · Paris$15.0M Seed
Nitrase Therapeutics
November 2021

Nitrase Therapeutics is developing drugs against newly discovered nitration enzyme(s).

Biotechnology · Jackson$7.0M Series A
Sphere Bio
October 2021

Sphere Bio specializes in tools for single cell analysis and isolation, facilitating discovery in the biotech field.

Biotechnology · Cambridge$41.4M Series Unknown
protera
July 2021

Protera is a biotechnology company that produce protein-based food ingredients.

Biotechnology · Neuilly-sur-seine$10.0M Series A
Mnemo Therapeutics
June 2021

Mnemo Therapeutics specializes in biotechnology and life science.

Biotechnology · Paris$90.0M Series A
Pyrowave
April 2021

Pyrowave closes the loop of polymer lifecycle by bringing plastic waste back to life.

Chemical · MontréalGrant
POLYNEURON
September 2020

Polyneuron is a pharmaceutical company, committed to the development of a new drug class for the treatment of autoimmune disorders.

Biotechnology · Basel$15.4M Series A
NodThera
June 2020

NodThera is a biotechnology company focused on the discovery and development of new treatments for diseases.

Biotechnology · Little Chesterford$55.0M Series B
Corvidia
March 2020

Corvidia Therapeutics focuses on the research and development of transformative therapies for cardio-renal diseases.

Biotechnology · Waltham$827K Convertible Note

Where Sofinnova Partners invests

Biotechnology20
Health Care8
Pharmaceutical8
Medical5
Medical Device4
Therapeutics4

About Sofinnova Partners's portfolio

How many companies has Sofinnova Partners invested in?

Sofinnova Partners has invested in 148 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Sofinnova Partners invest in?

Sofinnova Partners's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Medical, Medical Device. The firm invests across 26 different industry categories.

What is Sofinnova Partners's largest investment?

Among tracked funding rounds, Amolyt Pharma received $138.6M in a Series C round. Sofinnova Partners's total known invested capital is $6.3B.

What is the average investment size for Sofinnova Partners?

Sofinnova Partners's average investment size is $48.1M across its portfolio of 148 companies.

What are Sofinnova Partners's most recent investments?

Recent Sofinnova Partners portfolio additions include Sitryx Therapeutics, Gradient Denervation Technologies, Corwave, Mozart Therapeutics, TISSIUM. These companies were founded in 2020 or later.

Reach the founders behind these 148 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →